Researchers have utilized optical coherence elastography (OCE) to map the spatial and temporal changes in corneal ...
A single Epioxa epi-on cross-linking treatment sustained a 1.9 D Kmax improvement through three years in keratoconus, with no ...
1d
Man who lost his sight in ‘complete blackout’ now styles celebrities after life-changing surgery
JJ Savani, 36, was forced to give up his NHS career after losing his sight but an anonymous donation helped him build a ...
Glaukos has the iDose TR, which moves it beyond surgical devices into sustained drug delivery. Read why I lean neutral on ...
Initial phaco for angle-closure glaucoma climbed to 48.4% in adults 50 and older, while surveys and IRIS data show shifting ...
LASIK can reduce dependence on glasses, but vision changes may occur months or years later. Refractive regression, dry eyes, ...
- Glaukos GKOS -- secures second J-code (J2789) for Epioxa, a corneal cross-linking therapy, effective July 1, 2026, expanding its Medicare billing capabilities beyond glaucoma surgeries.
Il Cross-Linking Plus combina tecniche per contrastare la progressione del cheratocono e migliorare la qualità visiva in ...
iDose TR also demonstrated a favorable safety profile through 3 months, with no treated-related adverse events of corneal endothelial cell loss or cystoid macular edema (CME), and no serious corneal ...
At month 3, the 149-eye trial found a 7.4 mmHg reduction with surgery alone; iDose had no serious corneal adverse events ...
NYU Langone ophthalmology faculty present clinical trial results and surgical strategies at the 2026 American Academy of ...
- Glaukos GKOS -6.32% (GKOS) stock fell 6.32% on Oct 8, 2026, despite $0.45B in trading volume, its highest daily turnover. - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results